Insights On Drug Discovery

  1. Peripheral Blood Mononuclear Cell (PBMC) Isolation Using Cell Fractionation Filters 5/28/2025

    Discover how this Peripheral Blood Mononuclear Cell (PBMC) isolation method can transform CAR-T manufacturing by reducing costs, accelerating timelines, and improving patient accessibility.

  2. Signature Of Base Editor RNA Edits And Reduced Exogenous RNA Editing 5/28/2025

    Learn how this groundbreaking method for distinguishing base editor-induced RNA edits can enhance the safety and efficacy of genomic medicines.

  3. Electroporation, LNPs For Targeted CRISPR/Cas9 Gene Editing In T-Cells 5/28/2025

    This study compared non-viral transfection methods in primary human T-cells, demonstrating the feasibility of an LNP-based process encapsulating CRISPR/Cas9 and HDR template DNA in a single payload.

  4. CRISPR-Associated RNA-Guided Nucleases For Precise Gene Editing 5/28/2025

    Explore how advanced CRISPR technologies and proprietary delivery systems are transforming genomic medicine by enabling precise gene editing for a wide range of therapeutic applications.

  5. CRISPR System Enables CNS Biodistribution, mHTT Protein Reduction 5/28/2025

    Discover how a diverse collection of RNA-guided nucleases, base editors, and reverse transcriptase editors with unique PAM recognition sequences can enable flexible and precise genome editing.

  6. AAV Vector Used To Deliver Gene Editing Tools To The Brain 5/28/2025

    Discover how LETI-101's promising preclinical results and advanced manufacturing strategies are advancing gene editing therapy for Huntington's Disease.

  7. Allele-Selective Editing Of mHTT Results In Protein Reduction 5/28/2025

    Review the data presented in this slideshow to understand how LETI-101’s precise gene editing technology and promising preclinical data are being used to advance Huntington’s Disease treatment.

  8. Innovations In Hybridoma-Based Therapeutic Antibody Discovery Against Type 1 Transmembrane Proteins 5/23/2025

    Leverage the PentaMice®-powered hybridoma discovery and humanization platform to develop high-affinity, cross-reactive monoclonal antibodies against Type I transmembrane protein targets.

  9. Antibody-Based Drug Discovery At The Speed Of Light 5/23/2025

    Review this end-to-end workflow, including First-to-Human antibody development strategies, the use of the PentaMice® platform for targeted immunization, and the precision of single B cell screening.

  10. In Vitro/In Vivo Permeability: A 4-Cell Line Study 5/21/2025

    Evaluate drug absorption potential across diverse cell barriers and transporter systems using our comparative permeability studies with a variety of cell lines and standard compounds.